Co-Host: Alexander Kutikov, MD, FACS
At the conclusion of these activities, participants will be able to:
1. Discuss the evolving landscape of adjuvant therapy for the treatment of RCC.
2. Identify best practices for risk assessment and patient selection for adjuvant RCC therapy.
3. Differentiate the roles of urologist and medical oncologist in the care of patients with RCC.
CME Available: auau.auanet.org/node/26087
This educational series is supported by independent educational grants from:
Amgen
Astellas
AstraZeneca
Bristol-Myers Squibb
Genomic Health
Merck
Pfizer, Inc.
Sanofi Genzyme
UroGen Pharma
